ArriVent doses first patient in Phase 1 trial of ARR — 002 dual — target ADC for ovarian, endometrial cancer
ArriVent dosed the first patient in a US Phase 1 trial of ARR-002 for ovarian and endometrial cancer. No clinical results have been presented yet; the update marks the study’s start rather than an efficacy or safety readout. ARR-002 is designed to target two tumor markers to improve drug delivery across tumors with mix